Drug Profile
NVR 3 778
Alternative Names: AL-3778; ALS-003778; JNJ-63595948; NVR-1221; NVR-3-778Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Novira Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in New Zealand (PO, Tablet)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Hepatitis-B(Combination therapy) in China (PO, Capsule)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Hepatitis-B(Combination therapy) in New Zealand (PO, Capsule)